Companies: 10,795·Total market cap: $144.5T
BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

BMRNNASDAQHealthcare● Active
$56.67
$-0.10(-0.18%)
Market Cap$11.0B
P/E Ratio
52W High$66.28
52W Low$49.26

BioMarin Pharmaceutical Inc. (BMRN) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

bmrn · stock forecast · 41 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 41 Wall Street analysts in the past 3 months

SellBuy

Buy

41 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
28
Hold
13
Sell
0
Strong Sell
0
Total: 41 · Buy rate: 68.3%

12-Month Price Target

High

$120

Consensus

$89.93

+58.8% upside

Low

$50.00

Median: $95 · Last Close: $56.62

The BioMarin Pharmaceutical Inc. (BMRN) analyst consensus is Buy, based on ratings from 41 Wall Street analysts over the past 3 months. The average 12-month BMRN price target is $89.93, representing +58.8% upside from the current price of $56.62.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $90 (58.8%)

Consensus Target

$89.93

58.8% upside

High Target

$120

111.9%

Low Target

$50

-11.7%

Current Price

$56.62

as of today

Based on analyst price targets, the BMRN stock price prediction for the next 12 months ranges from $50 to $120. The consensus BMRN price forecast of $89.93 implies 58.8% upside from the current price of $56.62.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$58.022.48%

1-day model range: $57.71–$58.33. Peak: $58.33 (+2.48%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$48-16.0%
2028$43-24.7%
2029$40-29.8%
2030$38-32.9%
2031-34.8%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

86%7%7%
12Buy
1Neutral
1Sell
RSI (14)68.7Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · BMRN · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$55.57BUY
MA 10$54.82BUY
MA 20$53.50BUY
MA 50$54.29BUY
MA 100$56.34BUY
MA 200$55.77BUY
Current $BMRN · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$55.94BUY
EMA 10$55.10BUY
EMA 20$54.39BUY
EMA 50$54.64BUY
EMA 100$55.42BUY
EMA 200$56.76SELL
Current $BMRN · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Canaccord Genuity2026-05-22
Maintains
BuyBuy
B of A Securities2026-05-19
Maintains
BuyBuy
HC Wainwright & Co.2026-05-18
Maintains
NeutralNeutral
Canaccord Genuity2026-05-07
Maintains
BuyBuy
Evercore ISI Group2026-05-05
Maintains
OutperformOutperform
RBC Capital2026-05-05
Maintains
Sector PerformSector Perform
Bernstein2026-05-05
Maintains
OutperformOutperform
Morgan Stanley2026-05-05
Maintains
OverweightOverweight
HC Wainwright & Co.2026-05-05
Maintains
NeutralNeutral
B of A Securities2026-03-11
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on BioMarin Pharmaceutical Inc. (BMRN) stock. Of the recent 350 rating actions, 22 were upgrades and 20 were downgrades. 41 analysts currently cover BMRN.

Analyst Recommendation Trends

Buy ratings26↑ +4
Hold ratings13↑ +2
Sell ratings00

BMRN analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 6 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$3.9B

↓ 19.5% YoY

Revenue Next Year

$4.5B

↑ 14.8% YoY

EPS This Year

$4.89

EPS Next Year

$6.57

↑ 34.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast BMRN EPS of $4.89 for the current fiscal year, based on estimates from 15 analysts. The BMRN revenue forecast is $3.9B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The BMRN stock forecast is supported by two independent data sources: analyst consensus ratings from 41 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BMRN price target is $89.93 (+58.8% upside), with an analyst consensus of Buy.

The BMRN short-term stock prediction for tomorrow is $58.02 (+2.48%). The BMRN stock price prediction for 2027 estimates an average of $48. The BMRN stock prediction for 2030 projects a range of $36–$40.

BioMarin Pharmaceutical Inc. trades on NASDAQ under the ticker BMRN. The BMRN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 68% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

BMRN forecast · 8 questions

According to 41 Wall Street analysts, the average 12-month BMRN price target is $89.93, with a high forecast of $120.00 and a low of $50.00. The median price target is shown in the chart above when available. This implies +58.8% potential upside from the current price of $56.62.

BMRN price targetWhat is BMRN price targetBMRN analyst price targetBMRN 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.